In Vitro and In Vivo Test of Boron Delivery Agent for BNCT

Sista Dyah Wijaya; Bagaswoto Poedjomartono; Yohannes Sardjono

doi:10.24246/ijpna.v4i2.39-44

Sista Dyah Wijaya Pharmaceutical Science and Technology, School of Pharmacy, Bandung Institute of Technology
Bagaswoto Poedjomartono Department of Radiology, Radio Nuclear Services, Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada
Yohannes Sardjono Pusat Sains Dan Teknologi Akselerator; Badan Tenaga Nuklir Nasional (PSTA BATAN) / Center of Science and Technology of Accelerator; National Nuclear Energy Agency

DOI: https://doi.org/10.24246/ijpna.v4i2.39-44

Keywords: in vivo, in vitro, boron delivery agent, BNCT, clinical studies

Abstract

BNCT is an alternate therapy for treating cancer. The principle of BNCT involves a neutron boron uptake and a fission reaction that produce alpha particles and Li ions with a high level of linear energy transfer in the tissue. It is effective in killing tumor cells. To administer boron in the tumor cells, a boron delivery agent is needed. Thus far, there are a variety of boron delivery agents that have been developed. To date, just two main boron-based drugs, BPA and BSH, have been used for clinical studies. Many other boron delivery agents have been evaluated in vivo and in vitro but have not been evaluated clinically. Therefore, the other boron delivery agents have not been used in BNCT clinical studies.

Downloads

Download data is not yet available.

References

1. Jacob, M., Varghese, J., Murray, R. K., & Weil, P. A. (2015). Cancer: An Overview. Harper’s Illustrated Biochemistry, 30e, 1–3. Retrieved from http://mhmedical.com/content.aspx?aid=1106061033
2. Credits, R. (2018). Cancer 12. Cancer, (September 2018), 2018. https://doi.org/10.1016/S2214-109X(16)30143-7.4
3. Takagaki, M., Sakai, R., Tanaka, T., Ohsawa, N., Akagi, H., & Ono, K. (2004). Boron neutron capture therapy for malignant brain tumors. KURRI Progress Report, 140. https://doi.org/10.2176/nmc.ra.2015-0297
4. Coderre, J. A., & Morris, G. M. (2006). The Radiation Biology of Boron Neutron Capture Therapy. Radiation Research, 151(1), 1. https://doi.org/10.2307/3579742
5. Practice, T. (2016). Boron Neutron Capture Therapy : Delivery Agents Used in, XX(1), 25–32.
6. Barth, R. F., Mi, P., & Yang, W. (2018). Boron delivery agents for neutron capture therapy of cancer. Cancer Communications, 38(1), 1–15. https://doi.org/10.1186/s40880-018-0299-7
7. Sivaev, I. B., & Bregadze, V. V. (2009). Polyhedral boranes for medical applications: Current status and perspectives. European Journal of Inorganic Chemistry, (11), 1433–1450. https://doi.org/10.1002/ejic.200900003
8. Sauerwein, W. A. G., Wittig, A., Moss, R., & Nakagawa, Y. (2012). Neutron capture therapy: Principles and applications. Neutron Capture Therapy: Principles and Applications, 9783642313, 1–553. https://doi.org/10.1007/978-3-642-31334-9
9. R.F., B., & A.H., S. (1997). Boron neutron capture therapy of brain tumors - Current status and future prospects. Journal of Neuro-Oncology, 33(1–2), 3–7. Retrieved from http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L27183 200
10. Nedunchezhian, K., Aswath, N., Thiruppathy, M., & Thirugnanamurthy, S. (2016). Boron neutron capture therapy - a literature review. Journal of Clinical and Diagnostic Research, 10(12), ZE01–ZE04. https://doi.org/10.7860/JCDR/2016/19890.9024
11. Coderre, J. A., Turcotte, J. C., Riley, K. J., Binns, P. J., Harling, O. K., & Kiger, W. S. (2003). Boron Neutron Capture Therapy: Cellular Targeting of High Linear Energy Transfer Radiation. Technology in Cancer Research and Treatment, 2(5), 355–375. https://doi.org/10.1177/153303460300200502
12. Wittig, A., Sauerwein, W. A., & Coderre, J. A. (2000). Mechanisms of transport of p-borono-phenylalanine through the cell membrane in vitro. Radiation Research, 153(2), 173–180. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/10629616
13. Liao, A. H., Chou, F. I., Kuo, Y. C., Chen, H. W., Kai, J. J., Chang, C. W., … Hwang, J. J. (2010). Biodistribution of phenylboric acid derivative entrapped lipiodol and 4-borono-2-18F-fluoro-l-phenylalanine-fructose in GP7TB liver tumor bearing rats for BNCT. Applied Radiation and Isotopes, 68(3), 422–426. https://doi.org/10.1016/j.apradiso.2009.12.033
14. Futamura, G., Kawabata, S., Nonoguchi, N., Hiramatsu, R., Toho, T., Tanaka, H., … Miyatake, S. I. (2017). Evaluation of a novel sodium borocaptate-containing unnatural amino acid as a boron delivery agent for neutron capture therapy of the F98 rat glioma. Radiation Oncology, 12(1), 1–11. https://doi.org/10.1186/s13014-017-0765-4
15. Otersen, B., Haritz, D., Grochulla, F., Bergmann, M., Sierralta, W., & Gabel, D. (1997). Binding and distribution of Na2B12H11SH on cellular and subcellular level in tumor tissue of glioma patients in boron neutron capture therapy. Journal of Neuro-Oncology, 33(1–2), 131–139.
16. R.F., B., M.G.H., V., O.K., H., W.S., K. I. I. I., K.J., R., P.J., B., … S., K. (2012). Current status of boron neutron capture therapy of high grade gliomas and recurrent head and neck cancer. Radiation Oncology, 7(1), 1–21. https://doi.org/10.1186/1748-717X-7-146
17. Luderer, M. J., De La Puente, P., & Azab, A. K. (2015). Advancements in Tumor Targeting Strategies for Boron Neutron Capture Therapy. Pharmaceutical Research, 32(9), 2824–2836. https://doi.org/10.1007/s11095-015-1718-y
18. Barth, R. F. (2015). From the laboratory to the clinic: How translational studies in animals have lead to clinical advances in boron neutron capture therapy. Applied Radiation and Isotopes, 106, 22–28. https://doi.org/10.1016/j.apradiso.2015.06.016
19. Hawthorne, M. F., & Lee, M. W. (2003). A critical assessment of boron target compounds for boron neutron capture therapy. Journal of Neuro-Oncology, 62(1–2), 33–45. https://doi.org/10.1023/A:1023253309343
20. Coderre, J. A., Ph, D., Turcotte, J. C., Riley, K. J., Ph, D., Binns, P. J., … Ph, D. (2003). Boron Neutron Capture Therapy : Cellular Targeting of High Linear Energy Transfer Radiation. 2(5). https://doi.org/10.1177/153303460300200502
21. Bhupathiraju, N. V. S. D. K., & Grac, M. (2013). Synthesis of Carborane-Containing Porphyrin Derivatives for the Boron Neutron Capture Therapy of Tumors. https://doi.org/10.1007/7081
22. Barth, R. F., Yang, W., Al-madhoun, A. S., Johnsamuel, J., Byun, Y., Chandra, S., … Eriksson, S. (2004). Boron-Containing Nucleosides as Potential Delivery Agents for Neutron Capture Therapy of Brain Tumors. 6287–6295.
23. Barth, R. F., Yang, W., Nakkula, R. J., Byun, Y., Tjarks, W., Chu, L., … Riley, K. J. (2015). Evaluation of TK1 targeting carboranyl thymidine analogs as potential delivery agents for neutron capture therapy of brain tumors. Applied Radiation and Isotopes, 1–5. https://doi.org/10.1016/j.apradiso.2015.06.031
24. Khalil, A., Ali, T., & Tjarks, W. (n.d.). N3-substituted thymidine bioconjugates for cancer therapy and imaging. 677–692.
25. Yang, W., Barth, R. F., Wu, G., Tjarks, W., Binns, P., & Riley, K. (2009). Boron neutron capture therapy of EGFR or EGFRvIII positive gliomas using either boronated monoclonal antibodies or epidermal growth factor as molecular targeting agents. Applied Radiation and Isotopes, 67(7-8 SUPPL.), 328–331. https://doi.org/10.1016/j.apradiso.2009.03.030
26. Wu, G., Yang, W., Barth, R. F., Kawabata, S., Swindall, M., Bandyopadhyaya, A. K., … Fenstermaker, R. A. (2007). Molecular targeting and treatment of an epidermal growth factor receptor-positive glioma using boronated cetuximab. Clinical Cancer Research, 13(4), 1260–1268. https://doi.org/10.1158/1078-0432.CCR-06-2399
27. Azab, A. K., Srebnik, M., Doviner, V., & Rubinstein, A. (2005). Targeting normal and neoplastic tissues in the rat jejunum and colon with boronated, cationic acrylamide copolymers. Journal of Controlled Release, 106(1–2), 14–25. https://doi.org/10.1016/j.jconrel.2005.03.015
28. Maitz, C. A., Khan, A. A., Kueffer, P. J., Brockman, J. D., Dixson, J., Jalisatgi, S. S., … Hawthorne, M. F. (2017). Validation and Comparison of the Therapeutic Efficacy of Boron Neutron Capture Therapy Mediated By Boron-Rich Liposomes in Multiple Murine Tumor Models. Translational Oncology, 10(4), 686–692. https://doi.org/10.1016/j.tranon.2017.05.003
29. Altieri, S., Balzi, M., Bortolussi, S., Bruschi, P., Ciani, L., Clerici, A. M., … Ristori, S. (2009). Carborane derivatives loaded into liposomes as efficient delivery systems for boron neutron capture therapy. Journal of Medicinal Chemistry, 52(23), 7829–7835. https://doi.org/10.1021/jm900763b
30. Kawabata, S., Miyatake, S. I., Nonoguchi, N., Hiramatsu, R., Iida, K., Miyata, S., … Ono, K. (2009). Survival benefit from boron neutron capture therapy for the newly diagnosed glioblastoma patients. Applied Radiation and Isotopes, 67(7-8 SUPPL.), 15–18. https://doi.org/10.1016/j.apradiso.2009.03.015
31. Achilli, C., Grandi, S., Ciana, A., Guidetti, G. F., Malara, A., Abbonante, V., … Minetti, G. (2014). Biocompatibility of functionalized boron phosphate (BPO 4 ) nanoparticles for boron neutron capture therapy (BNCT) application. Nanomedicine: Nanotechnology, Biology, and Medicine, 10(3), 589–597. https://doi.org/10.1016/j.nano.2013.10.003
32. Noguchi, H., Matsushita, M., Kobayashi, N., Levy, M. F., & Matsumoto, S. (2010). Recent advances in protein transduction technology. Cell Transplantation, 19(6–7), 649–654. https://doi.org/10.3727/096368910X508744
33. Michiue, H., Sakurai, Y., Kondo, N., Kitamatsu, M., Bin, F., Nakajima, K., … Matsui, H. (2014). The acceleration of boron neutron capture therapy using multi-linked mercaptoundecahydrododecaborate (BSH) fused cell-penetrating peptide. Biomaterials, 35(10), 3396–3405. https://doi.org/10.1016/j.biomaterials.2013.12.055
34. Meiyanto, E. (2014). Pengembangan boron carrying pharmaceuticals untuk mendukung terapi kanker berbasis bnct. 10–11.
35. Poedjomartono, B., Afkari, H., Meiyanto, E., Bangun, A. A., & Sardjono, Y. (2019). Boron Neutron Capture Therapy for Cancer: Future Prospects in Indonesia. ASEAN Journal on Science and Technology for Development, 35(3), 199–201. https://doi.org/10.29037/ajstd.510
36. Qodria, L., Hairunisa, I., Utomo, R. Y., Hermawan, A., & Meiyanto, E. (2019). Anti-metastatic Activity of Curcumin Analog Pentagamaboronon-0-Sorbitol Against HER2-overexpressed MCF-7 Breast Cancer Cells. Indonesian Journal of Cancer Chemoprevention, 9(3), 118. https://doi.org/10.14499/indonesianjcanchemoprev9iss3pp118-125